The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1486
January 18, 2016
View Complete Issue         Table of Contents 2019 
Durlaza - A 24-Hour Extended-Release Aspirin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Durlaza - A 24-Hour Extended-Release Aspirin
January 18, 2016 (Issue: 1486)
The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Durlaza - A 24-Hour Extended-Release Aspirin
Article code: 1486a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.